世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000038536

腸内細菌製剤およびマイクロバイオームCDMO市場-規模、シェア、動向分析レポート、およびセグメント予測、2024〜2030

Grand View Research Inc.

Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Trends Analysis Report, And Segment Forecasts, 2024- 2030

発刊日 2024/06

言語英語

体裁PDF/137ページ

ライセンス/価格137ページ

0000038536

Individual
Team
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

腸内細菌製剤およびマイクロバイオームCDMOの市場規模、シェア、動向分析レポート:用途別 (C.ディフィクル、クローン病、IBS、糖尿病、その他)、地域別 (MEA、アジア太平洋)、セグメント予測、2024-2030

市場規模と動向

世界の腸内細菌製剤およびマイクロバイオームCDMO市場の規模は、2023年に3,184万ドルと推定され、2024年から2030年にかけて37.77%のCAGRで成長すると予想されます。炎症性腸疾患、がん、神経疾患などのさまざまな疾患の治療における腸内細菌製剤やマイクロバイオームベースの治療薬の潜在的な利点の重要性が、患者や医療従事者の間で高まっていることが、市場の成長を促進する主な要因となっています。さらに、慢性疾患の有病率の増加と個別化医療の需要の高まりも、腸内細菌製剤とマイクロバイオームベースの治療薬市場を拡大しています。

レポート詳細

目次

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Regional Scope
1.2 Estimates And Forecast Timeline
1.3 Market Definition
1.4 Research Methodology
1.5 Information Procurement
1.5.1 Information Analysis
1.5.2 Market Formulation & Data Visualization
1.5.3 Data Validation & Publishing
1.6 Research Scope And Assumptions
1.6.1 Commodity Flow Analysis
1.6.2 Top Down Market Estimation
1.6.3 Region/Country Based Segment Share Calculation.
1.6.4 Multivariate Analysis
1.6.5 Live Biotherapeutic Products And Microbiome CDMO Market: Cagr Calculation
1.7 List of Secondary Sources
1.8 List of Abbreviations

Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot

Chapter 3 Live Biotherapeutic Products And Microbiome CDMO Market: Variables, Trends, & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Live Biotherapeutic Products And Microbiome CDMO Dynamics
3.3 Market Dynamics
3.3.1 Market Driver Impact Analysis
3.3.1.1 High Potential Of Live Biotherapeutic Products And Microbiome In Treating Chronic & Infectious Diseases
3.3.1.2 Increase In Clinical Research On Live Biotherapeutic Products
3.3.1.3 Increasing Demand For One-Stop-Shop CDMOs
3.3.2 Market Restraint Analysis
3.3.2.1 Compliance Issues In Outsourcing
3.3.2.2 Availability Of Substitutes
3.4 Live Biotherapeutic Products and Microbiome CDMO Market: Analysis Tools
3.4.1 Porter’s Five Forces Analysis
3.4.2 Pestel Analysis
3.5 Live Biotherapeutic Products And Microbiome CDMO Market, By Application Type
3.5.1 Global Live Biotherapeutic Products And Microbiome CDMO Market, By Type, 2023 (Percent Share %)
3.6 Impact Of Covid-19 On Live Biotherapeutic Products And Microbiome CDMO Market
3.6.1 Disrupted Clinical Trials
3.7 Post COVID-19 Market Scenario

Chapter 4 Live Biotherapeutic Products And Microbiome CDMO Market: Application Analysis
4.1 Live Biotherapeutic Products and Microbiome CDMO Market by Application Segment: Key Takeaways
4.2 Live Biotherapeutic Products and Microbiome CDMO Market: Application Movement Analysis
4.3 Live Biotherapeutic Products and Microbiome CDMO Market Estimates & Forecast by Application (USD Million)
4.4 C. difficile
4.4.1 C. Difficile Market, 2018 - 2030 (USD Million)
4.5 Crohn's disease
4.5.1 CROHN'S Disease Market, 2018 - 2030 (USD Million)
4.6 IBS
4.6.1 IBS Market, 2018 - 2030 (USD Million)
4.7 Diabetes
4.7.1 Diabetes Market, 2018 - 2030 (USD Million)
4.8 Others
4.8.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 Live Biotherapeutic Products And Microbiome CDMO Market: Regional Analysis
5.1 Live Biotherapeutic Products and Microbiome CDMO: Market Share Analysis, 2023 & 2030
5.2 Live Biotherapeutic Products and Microbiome CDMO: Market Estimates and Forecast, by Region (USD Million)
5.3 North America
5.3.1 Competitive Scenario
5.3.2 Regulatory Scenario
5.3.3 North America Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.3.4 U.S.
5.3.4.1 Key Country Dynamics
5.3.4.2 Competitive Scenario
5.3.4.3 U.S. Live Biotherapeutic Products and Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.3.5 Canada
5.3.5.1 Key Country Dynamics
5.3.5.2 Competitive Scenario
5.3.5.3 Canada Live Biotherapeutic Products and Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4 Europe
5.4.1 Competitive Scenario
5.4.2 Regulatory Scenario
5.4.3 Europe Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.4 UK
5.4.4.1 Key Country Dynamics
5.4.4.2 Competitive Scenario
5.4.4.3 UK Live Biotherapeutic Products and Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.5 Germany
5.4.5.1 Key Country Dynamics
5.4.5.2 Competitive Scenario
5.4.5.3 Germany Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.6 France
5.4.6.1 Key Country Dynamics
5.4.6.2 Competitive Scenario
5.4.6.3 France Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.7 Italy
5.4.7.1 Key Country Dynamics
5.4.7.2 Competitive Scenario
5.4.7.3 Italy Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.8 Spain
5.4.8.1 Key Country Dynamics
5.4.8.2 Competitive Scenario
5.4.8.3 Spain Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.4.9 Denmark
5.4.9.1 Key Country Dynamics
5.4.9.2 Competitive Scenario
5.4.9.3 Denmark Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.10 Sweden
5.4.10.1 Key Country Dynamics
5.4.10.2 Competitive Scenario
5.4.10.3 Sweden Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.4.11 Norway
5.4.11.1 Key Country Dynamics
5.4.11.2 Competitive Scenario
5.4.11.3 Norway Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5 Asia Pacific
5.5.1 Competitive Scenario
5.5.2 Regulatory Scenario
5.5.3 Asia Pacific Live Biotherapeutic Products And Microbiome CDMO Market, 2018 - 2030 (USD Million)
5.5.4 China
5.5.4.1 Key Country Dynamics
5.5.4.2 Competitive Scenario
5.5.4.3 China Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.5 Japan
5.5.5.1 Key Country Dynamics
5.5.5.2 Competitive Scenario
5.5.5.3 Japan Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.6 India
5.5.6.1 Key Country Dynamics
5.5.6.2 Competitive Scenario
5.5.6.3 India Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.7 Australia
5.5.7.1 Key Country Dynamics
5.5.7.2 Competitive Scenario
5.5.7.3 Australia Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.8 Thailand
5.5.8.1 Key Country Dynamics
5.5.8.2 Competitive Scenario
5.5.8.3 Thailand Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.5.9 South Korea
5.5.9.1 Key Country Dynamics
5.5.9.2 Competitive Scenario
5.5.9.3 South Korea Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6 Latin America
5.6.1 Competitive Scenario
5.6.2 Regulatory Scenario
5.6.3 Latin America Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.4 Brazil
5.6.4.1 Key Country Dynamics
5.6.4.2 Competitive Scenario
5.6.4.3 Brazil Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.5 Mexico
5.6.5.1 Key Country Dynamics
5.6.5.2 Competitive Scenario
5.6.5.3 Mexico Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.6.6 Argentina
5.6.6.1 Key Country Dynamics
5.6.6.2 Competitive Scenario
5.6.6.3 Argentina Live Biotherapeutic Products and Microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
5.7 MEA
5.7.1 Competitive Scenario
5.7.2 Regulatory Scenario
5.7.3 MEA Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.7.4 South Africa
5.7.4.1 Key Country Dynamics
5.7.4.2 Competitive Scenario
5.7.4.3 South Africa Live Biotherapeutic Products And Microbiome CDMO Market Estimates And Forecasts, 2018 - 2030 (USD Million)
5.7.5 Saudi Arabia
5.7.5.1 Key Country Dynamics
5.7.5.2 Competitive Scenario
5.7.5.3 Saudi Arabia Live Biotherapeutic Products and Microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.6 UAE
5.7.6.1 Key Country Dynamics
5.7.6.2 Competitive Scenario
5.7.6.3 UAE Live Biotherapeutic Products and Microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
5.7.7 Kuwait
5.7.7.1 Key Country Dynamics
5.7.7.2 Competitive Scenario
5.7.7.3 Kuwait Live Biotherapeutic Products and Microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6 Live Biotherapeutic Products And Microbiome CDMO Market: Competitive Landscape
6.1. Market Participant Categorization
6.2. Market Position Analysis, 2022/2023 (Heat Map Analysis)
6.3. Company Profiles
6.3.1. Strategy Mapping
6.3.2. Service Launches
6.3.3. Acquisition
6.3.4. Partnerships/Agreements/Collaboration
6.3.5. Expansions
6.4. Vendor Landscape
6.4.1. Key company market share analysis, 2023
6.4.2. Arrant Bio
6.4.2.1. Company overview
6.4.2.2. Financial performance
6.4.2.3. Service benchmarking
6.4.2.4. Strategic initiatives
6.4.3. 4D Pharma
6.4.3.1. Company overview
6.4.3.2. Financial performance
6.4.3.3. Service benchmarking
6.4.3.4. Strategic initiatives
6.4.4. Cerbios
6.4.4.1. Company overview
6.4.4.2. Financial performance
6.4.4.3. Service benchmarking
6.4.4.4. Strategic initiatives
6.4.5. Biose Industrie
6.4.5.1. Company overview
6.4.5.2. Financial performance
6.4.5.3. Service benchmarking
6.4.5.4. Strategic initiatives
6.4.6. Assembly Biosciences, Inc
6.4.6.1. Company overview
6.4.6.2. Financial performance
6.4.6.3. Service benchmarking
6.4.6.4. Strategic initiatives
6.4.7. Wacker Chemie AG
6.4.7.1. Company overview
6.4.7.2. Financial performance
6.4.7.3. Service benchmarking
6.4.7.4. Strategic initiatives
6.4.8. Quay Pharmaceuticals
6.4.8.1. Company overview
6.4.8.2. Financial performance
6.4.8.3. Service benchmarking
6.4.8.4. Strategic initiatives
6.4.9. NIZO
6.4.9.1. Company overview
6.4.9.2. Financial performance
6.4.9.3. Service benchmarking
6.4.9.4. Strategic initiatives
6.4.10. LONZA
6.4.10.1. Company overview
6.4.10.2. Financial performance
6.4.10.3. Service benchmarking
6.4.10.4. Strategic initiatives
6.4.11. Inpac Probiotics
6.4.11.1. Company overview
6.4.11.2. Financial performance
6.4.11.3. Service benchmarking
6.4.11.4. Strategic initiatives

List of Tables
Table 1 List of abbreviation
Table 2 North America live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 3 North America live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 4 U.S. live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 5 Canada live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 6 Europe live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 7 Europe live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 8 UK live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 9 Germany live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 10 France live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 11 Italy live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 12 Spain live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 13 Denmark live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 14 Sweden live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 15 Norway live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 16 Asia Pacific live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 17 Asia Pacific live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 18 Japan live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 19 China live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 20 India live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 21 Australia live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 22 South Korea live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 23 Thailand live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 24 Latin America live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 25 Latin America live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 26 Brazil live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 27 Mexico live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 28 Argentina live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 29 MEA live biotherapeutic products and microbiome CDMO market, by region, 2018 - 2030 (USD Million)
Table 30 MEA live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 31 South Africa live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 32 Saudi Arabia live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 33 UAE live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)
Table 34 Kuwait live biotherapeutic products and microbiome CDMO market, by application, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Live biotherapeutic products and microbiome CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Data Analysis Models
Fig. 5 Market Formulation And Validation
Fig. 6 Data Validating & Publishing
Fig. 7 Commodity flow analysis
Fig. 8 Market snapshot
Fig. 9 Segment snapshot
Fig. 10 Competitive landscape snapshot
Fig. 11 Parent market outlook, 2023 USD (Billion)
Fig. 12 Ancillary market outlook, 2023 (USD Billion)
Fig. 13 Live biotherapeutic products and microbiome CDMO market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 Live biotherapeutic products and microbiome CDMO market: PESTEL analysis
Fig. 16 Live biotherapeutic products and microbiome CDMO market, by type, 2023 (Revenue percent share %)
Fig. 17 Companies with affected trials, by size
Fig. 18 Affected trials, by study phase
Fig. 19 Clinical trial scenario (as of January 2022)
Fig. 20 Live biotherapeutic products and microbiome CDMO market: Application outlook and key takeaways
Fig. 21 Live biotherapeutic products and microbiome CDMO market: Application movement analysis
Fig. 22 C. difficile market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Crohn's disease market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 IBS market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Regional market: Key takeaways
Fig. 28 Regional outlook, 2023 & 2030
Fig. 29 Regional outlook, 2023 & 2030
Fig. 30 North America live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Key country dynamics
Fig. 32 U.S. live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Key country dynamics
Fig. 34 Canada live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Europe live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Key country dynamics
Fig. 37 UK live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Key country dynamics
Fig. 39 Germany live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Key country dynamics
Fig. 41 France live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Key country dynamics
Fig. 43 Italy live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Key country dynamics
Fig. 45 Spain live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Key country dynamics
Fig. 47 Denmark live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Sweden live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Key country dynamics
Fig. 51 Norway live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Asia Pacific live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Key country dynamics
Fig. 54 China live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 Japan live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Key country dynamics
Fig. 58 India live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Key country dynamics
Fig. 60 Australia live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Thailand live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Key country dynamics
Fig. 64 South Korea live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Latin America live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Key country dynamics
Fig. 67 Brazil live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Key country dynamics
Fig. 69 Mexico live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 Argentina live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 MEA live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Key country dynamics
Fig. 74 South Africa live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Key country dynamics
Fig. 76 Saudi Arabia live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 UAE live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Key country dynamics
Fig. 80 Kuwait live biotherapeutic products and microbiome CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Market participant categorization
Fig. 82 Heat map analysis
Fig. 83 Market participant categorization

この商品のレポートナンバー

0000038536

TOP